Search

Keratocytes are specialized, neural crest-derived mesenchymal cells occupying approximately 3% of the corneal stromal volume. They reside between the collagen lamellae and are responsible for the secretion of extracellular matrix macromolecules, thus contributing to the corneal transparency and integrity. During the regeneration process after infection, traumata and refractive surgery, the keratocytes undergo transition into divergent phenotypes, which are referred to as 'activated keratocytes'. Quite shortly after injury, the keratocytes lose their quiescence, enter into the cell cycle and migrate toward the site of injury. In certain types of injury, which affect the integrity of basement membrane, activated keratocytes also participate in wound closure by production of α-smooth muscle actin (α-SMA). Since the activated keratocytes are the major cell type contributing to tissue repair during corneal wound healing, their morphological and biochemical properties have been studied in details in experimental studies using light and electron microscopy. More recently, emerging of in vivo microscopy techniques has opened new possibilities to investigate cornea in vivo. The non-invasive nature of this imaging modality enables repeated examination of the same tissue over time and is an ideal tool to rapidly and accurately investigate corneal wound healing. However, the in vivo data on activated keratocytes are not as uniform as data from experimental ex vivo studies. There is still inconsistency in the literature findings on activated phenotypes, and often the described morphologies cannot be appreciated in in vivo images. In this article, a literature review was performed in order to interpret the morphology of different activated phenotypes, based on biological processes underlying the morphological alterations. [ABSTRACT FROM AUTHOR]

Background: Niemann-Pick type C1 (NPC1) disease is an inherited lysosomal storage disease caused by mutation of the Npc1 gene, resulting in a progressive accumulation of unesterified cholesterol and glycolipids in lysosomes of multiple tissues and leading to neurodegeneration and other disease. In Npc1 mutant mice, retinal degeneration including impaired visual function, lipofuscin accumulation in the pigment epithelium and ganglion cells as well as photoreceptor defects has been found. However, the pathologies of other individual cell types of the retina in Npc1 mutant mice are still not fully clear. We hypothesized that horizontal cells, amacrine cells, bipolar cells and glial cells are also affected in the retina of Npc1 mutant mice. Results: Immunohistochemistry and electron microscopy were used to investigate pathologies of ganglion cells, horizontal cells, amacrine cells, bipolar cells, and optic nerves as well as altered activity of glial cells in Npc1 mutant mice. Electron microscopy reveals that electron-dense inclusions are generally accumulated in ganglion cells, bipolar cells, Müller cells, and in the optic nerve. Furthermore, abnormal arborisation and ectopic processes of horizontal and amacrine cells as well as defective bipolar cells are observed by immunohistochemistry for specific cellular markers. Furthermore, hyperactivity of glial cells, including astrocytes, microglial cells, and Müller cells, is also revealed. Conclusions: Our data extend previous findings to show multiple defects in the retina of Npc1 mutant mice, suggesting an important role of Npc1 protein in the normal function of the retina. [ABSTRACT FROM AUTHOR]

Purpose: Keratoconus is a predominantly bilateral form of corneal degeneration that is associated with central thinning and cone-shaped bulging of the cornea usually accompanied by a progressive reduction in visual acuity. A recent therapeutic option is cross-linking, a procedure designed to prevent the progression of keratoconus by the photochemical cross-linkage of collagen fibers. Patients and Methods: Eight eyes in 8 patients with progressive keratoconus were treated by the photochemical cross-linking method using riboflavin and UVA light. In addition to the usual ophthalmological examinations, patients were examined pre- and postoperatively by confocal in vivo laser scanning microscopy. Follow-up examinations were performed at 2 weeks and at 2, 4, 6 and 12 months postoperatively. Results: Complete regeneration of corneal epithelium was detected by 2 weeks after therapy at the latest. The sub-basal nerve plexus could not be visualized by confocal microscopy after treatment. Immediately after treatment, the anterior corneal stroma had a honeycombed appearance but without the typical hyperreflective keratocyte nuclei. At about 6 months postoperatively, the corneal stroma had virtually regained its normal configuration. After therapy, confocal microscopy revealed that corneal endothelium was normal in terms of cell density and morphology at every time point. Conclusions: Confocal in vivo laser scanning microscopy is an investigative technique that permits reproducible visualization of structural changes in the cornea (epithelium, stroma and endothelium) following collagen cross-linking with riboflavin and UVA light. Once epithelial healing is complete, the epithelium and endothelium appear to be unaffected by the treatment. The most noteworthy structural changes, which are detected on confocal microscopy shortly after treatment, involve the anterior and middle corneal stroma. Over the course of time, up to 12 months postoperatively, these changes show a definite tendency to regress. Copyright © 2010 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

The introduction of disease-specific therapy for patients with type I Gaucher disease (GD1) was a revolution in the management of patients, but not without cost. Thus, the management of mildly affected patients is still debated. We herein report a long-term follow-up (median (range) of 20 (5–58) years) of 103 GD1 patients who have never received enzymatic or substrate reduction therapy. The median (range) platelet count and hemoglobin levels in last assessment of all but six patients who refused therapy (although recommended and approved) were 152 (56–408) × 103/mL and 13.1 (7.6–16.8) g/dL, respectively. Most patients had mild hepatosplenomegaly. Nine patients were splenectomized. No patient developed clinical bone disease. The median (range) lyso-Gb1 levels at last visit was 108.5 (8.1–711) ng/mL; lowest for patients with R496H/other and highest for patients refusing therapy. This rather large cohort with long follow-up confirms that mildly affected patients may remain stable for many years without GD-specific therapy. The challenge for the future, when newborn screening may detect all patients, is to be able to predict which of the early diagnosed patients is at risk for disease-related complications and therefore for early treatment, and who may remain asymptomatic or minimally affected with no need for disease-specific therapy. [ABSTRACT FROM AUTHOR]